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ABSTRACT  Adoptive immunotherapy (AIT) using autologous lymphocytes activated ex vivo 
with antigen stimulation, including zoledronate-activated killer (ZAK) cells, were conducted in 
the treatment of patients with incurable cancer.  Efficacy, safety and treatment feasibility were 
all evaluated, retrospectively. Two-hundred and twenty-eight patients were enrolled and 198 
were treated with AIT every 3 weeks. Success of effector cell generation was evident in 94.0 
% of the culture. A mean number of the administration was 6.8 times with a total number of 
5.8 x 109 cells. Survival analysis implied marginal benefit of AIT in addition to chemotherapy in 
lung, colorectal, pancreatic cancers, especially in biliary cancer, showing the median survival 
time of 11.9 months. Objective tumor response of 3 CR and 6 PR was observed in colorectal, 
pancreatic, breast and biliary cancers, showing a response rate of 13.2 %. Improvement of QOL 
was replied in 33 % patients and FACT-BRM analysis demonstrated significant improvements 
in physical, social, emotional and functional well-beings. Together, it is suggested that AIT 
using autologous lymphocytes activated ex vivo with antigen stimulation, including ZAK cells, is 
safe and feasible, and may be effective in prolonging survival and improving QOL for patients 
with incurable cancer.
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INTRODUCTION
   The discovery and molecular cloning of the 
crucial lymphocyte growth factor, interleukin-2 
(IL-2), has facilitated the clinical application of 
adoptive immunotherapy (AIT) for cancer treatment 
using autologous lymphocytes activated in vitro 
with IL-2 1）. We carried out ex vivo cell therapy 
for cancer treatment using activated autologous 
lymphocytes, including lymphokine-activated 
killer (LAK) cells, tumor-infiltrating lymphocytes 
(TILs), and tumor-sensitized lymphocytes, but 
tumor responses are limited with regard to quality 
of life (QOL) in locoregional administration for 
malignant effusion from gastrointestinal cancers 2）. 
Other researchers have demonstrated survival 
benefits in hepatocellular carcinoma patients using 
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postoperative LAK cell transfer after surgery 3） and 
in lung cancer patients using LAK cell transfer in 
combination of chemoradiotherapy 4）. Thereafter, 
we introduced the use of dendritic cells (DCs) and 
tumor antigens into the effector cell generation 
system, although tumor responses were still limited 5）.
   Zoledronate, a bisphosphonate widely used to 
treat bone diseases, have been described to stimulate 
anti-tumor effector lymphocytes with γδ-type T cell 
receptors in the presence of DCs 6）. γδT cells have 
been described to contain the properties associated 
with the innate immune system, HLA-unrestricted 
tumor recognition manner, high cytotoxic and 
proliferative potentials 7）. Sakamoto et al.8） and 
Noguchi et al.9） reported the AIT trial using 
zoledronate-activated lymphocytes for patients with 
cancer and described its safety and feasible profiles, 
indicating that AIT of cancer using zoledronate-
activated lymphocytes may be highly promising 
for clinical use. We have previously established the 
generation system of zoledronate-activated killer 
(ZAK) cells 10）. In the present study, we conducted 
an observation study of AIT using autologous 
lymphocytes activated ex vivo  with antigen 
stimulation, including ZAK cells, for patients with 
incurable cancer. We will show the possible survival 
benefit as well as the benefit of QOL of AIT, 
especially in biliary cancer patients treated with 
chemotherapy.
MATERIALS AND METHODS
Study design
   This treatment is an observational cohort study 
conducted in Kawasaki Medical School Hospital 
between May 2009 and August 2012. All patient 
participants had a diagnosis of incurable cancer 
with a performance status capable of visiting 
our  outpat ient  c l in ic  and s igned informed 
consent. Patients were excluded if they met the 
following criteria of consecutive use of steroid 
or immunosuppressant, autoimmune diseases, 
difficulty to manage at outpatient clinic, and 
uncontrolled complications.  Participants were 
considered for study until deceased, withdrawal of 
consent, or follow-up contact was lost. There were 
no protocol-specified treatments or assessments. All 
aspects of patients’ treatments over time, including 
specific chemotherapy agents and/or combinations, 
and the dose, schedule, and duration of AIT, were 
determined by a physician. This retrospective 
analysis was reviewed and approved by a central 
institutional review board (No. 1050).
ZAK cell generation and transfer
   Heparinized venous blood (10 ml) was obtained 
from patients, and buffy coat and plasma were 
immediately separated by centrifugation (2,000 rpm, 
30 min). The buffy coat was resuspended in RPMI-
1640 medium, and the suspension was layered 
on Lymphoprep (Muto Pure Chemicals, Tokyo). 
Peripheral blood mononuclear cells (PBMCs) were 
isolated by gradient centrifugation (2,000 rpm, 30 
min) and washed twice. ZAK cell generation has 
been mentioned in detail elsewhere 10）. PBMCs 
were resuspended in the medium containing 2% 
heat-inactivated autologous plasma, 100 U/ml IL-2 
(Sionogi, Osaka), and 1 μM zoledronate (Novartis, 
Tokyo) at a density of 1 x 107/ml. After incubation 
in a humidified atmosphere of 5% CO2 for 24 hours 
at 37℃, cells (2 x 106/ml) were transferred into 
new medium containing plasma and IL-2 except 
of zoledronate (complete medium, CM), followed 
by further incubation for 10 to 14 days. CM was 
changed every 3 or 4 days. Cells were harvested 
by centrifugation, washed twice, resuspended in 
100 ml saline after filtering through 200 μm mesh 
(Becton Dickinson), and administered intravenously 
for 30 min every 3 weeks. At each infusion, patients 
had blood drawn to prepare ZAK cells for the next 
transfer. Bacterial and endotoxin examinations were 
completed before each administration to make sure 
no contaminations.
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Clinical efficacy
   Survival of the patients was collected from patient 
record. If unknown, prognosis was requested by 
mail to the doctor-in-charge. Objective tumor 
response was evaluated by computed tomographic 
examinations. Data were collected at baseline and 
every 3 months. Complete response (CR), partial 
response (PR), stable disease (SD) and progressive 
disease (PD) was determined by the investigator 
according to the RECIST 11）. 
QOL analysis
   Assessment of quality of life was performed by 
FACT-BRM 12） before and after 3 administrations of 
ZAK cells. Documents were collected by research 
coordinators and analyzed independently of 
physicians.
Statistics
   Statistical analysis was conducted on the SPSS 
program. Survival curve was drawn by Kapran-
Meyer analysis to estimate median survival time 
(MST). For QOL analysis, paired Student's t -test 
was carried out. Values are presented as mean ± 
standard deviation, and p<0.05 was defined as 
statistically significant.
RESULTS
Characteristics of patients enrolled
   Two hundred and twenty-eight patients including 
134 males and 94 females, ranging 28 to 88 in 
age were entered in the trial, although 30 patients 
could not be treated with AIT because of disease 
progression in 26 patients and no lymphocyte 
growth in 4 patients (Table 1). Primary lesion of 
cancer consisted of 54 pancreatic, 43 colorectal, 
31 stomach, 17 biliary, 14 lung, 10 esophageal, 
10 breast, and 50 other organ cancers. Metastatic 
organs were liver, lung, lymph nodes, peritoneum, 
bone, and brain, and most patients were received 
concurrent anti-cancer treatment, as shown in Table 1.
Feasibility of ZAK cell generation and transfer
   Generation of ZAK cells was carried out 1,359 
times in total, and 1,277 cultures of those (94.0%) 
were uneventful (Table 2). Transfer of ZAK cells 
were completed once to 4 times for 90, 5 to 9 times 
for 75, 10 to 19 times for 20, 20 to 29 times for 
9, and more than 30 times for 4 patients, a mean 
value of which was 6.8 times. A mean number of 
total cells transferred was 5.4 x 109 cells in all the 
patients treated, and 8.7 x 109 cells in those treated 
more than 5 times. No detection of bacteria and 
endotoxin was evidenced through all the cultures.
Table 1. Patients enrolled in the AIT trial
Total No.
Male/Female
Treated/untreated
Age (range, mean)
Primary organ
Pancreas
Colorectal
Stomach
Biliary
Lung
Esophagus
Breast
Others
Metastasis
Liver
lung
Lymph node
Peritoneum
Bone
Brain
Concurrent treatments
Chemotherapy
Radiation
None
228
134/94
198/30
28-88, 60.7
54
43
31
17
14
10
10
50
65
55
32
24
23
3
138
3
59
Table 2. Feasibility of AIT
Total culture No.  1,359
　 　Success of culture  1,277 (94.0%)
Administration No.
　 　0   　 30*
　 　1-4   　 90
　 　5-9   　 75
　 　10-19   　 20
　 　20-29   　  9
　 　30<   　  4
　 　(mean 6.8 times)
Total cell No. administered (mean)
　 　All Pts treated  5.4 x 10^9
　 　Pts treated 5 times< 8.7 x 10^9
Contamination detected     0 (1)**
Endotoxin >4.0  　　0
* 4, no lymphocyte growth; 26, disease progression
**Once positive, but ﬁnally negative at reexamination
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Survival analysis
   Survival analysis was summarized in Table 3. 
Under the median follow-up time of 8.9 months 
(range: 0.9-35.5), median survival time (MST) was 
8.0 in lung, 5.4 in stomach, 14.6 in colorectal, 5.7 
in pancreatic, and 11.9 months in biliary cancer 
patients.
Tumor response
   Tumor response was shown in Table 4. Of 198 
patients treated, 108 patients received more than 
5 administrations of ZAK cells, of which 68 were 
evaluable for objective tumor responses. CR was 
observed in 3 including pancreas, biliary, and breast 
cancer patients, in whom oral fluorouracil was 
concomitantly administered with ZAK cells. PR was 
shown in 6 including 5 colorectal and one breast 
cancer patients. Response rate was 9 in 68 patients 
evaluated (13.2 %). No objective tumor response 
was evident in lung and stomach cancer patients. 
However, 40 patients (58.8 %) showed SD status, so 
that tumor control rate was estimated as 72.1 %.
Adverse events
   Of 198 patients treated, 2 showed temporally 
low grade fever after ZAK cell administration. No 
adverse events relevant with ZAK cell transfer 
higher than grade 2 were observed in all the patients 
treated.
QOL analysis
   QOL analysis was shown in Table 5. The scores of 
social and emotional well-being were significantly 
improved after ZAK cell administration (p<0.05), as 
shown in Table 4. In the assessment of physical or 
functional well-being, some questionnaires showed 
trends to be improved after ZAK cell transfers 
(p<0.1). Moreover, the improvement of physical and 
mental queries was replied from 65 of 198 (33 %) 
patients at a regular hospital visit after 3 ZAK cell 
transfers.
DISCUSSION
   We conducted an observation study of AIT 
using autologous lymphocytes activated ex vivo 
with antigen stimulation, including ZAK cells, in 
Table 3. Overall survival
MST
(months)
95% CI
(months)
Lung
Stomach
Colorectal
Pancreas
Biliary
8.0
5.4
14.6
5.7
11.9
6.1-10.0
0.5-10.4
7.6-21.6
3.6-7.8
5.1-18.8
Table 4. Objective responses treated with AIT
Objective responses
CR PR SD PD Total
Lung
Stomach
Colorectal
Pancreatic
Biliary
Breast
0
0
0
1
1
1
0
0
5
0
0
1
4
10
9
11
5
3
1
2
5
5
3
6
5
12
19
17
9
9
Total 3 6 40 19 68
Table 5. QOL analysis according to FACT-BRM
before after difference p value
PHYSICAL WELL-BEING
　   　I am bothered by side effects of treatment
SOCIAL/FAMILY WELL-BEING
　   　I get support from my friends
　   　I feel close to my partner
　   　(or the person who is my main support)
EMOTIONAL WELL-BEING
　　　　　　I worry that my condition will get worse
FUNCTIONAL WELL-BEING
　　　　　　I am able to enjoy life
　　　　　　I have accepted my illness
1.10
1.61
3.31
2.27
2.22
2.87
0.81
1.94
3.61
1.92
2.51
3.06
-0.288
+0.327
+0.294
-0.346
+0.294
+0.192
0.075
0.077
0.003
0.038
0.062
0.096
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treating patients with incurable cancer. Through 
more than 1,000 generations of ZAK cells, 94% 
cultures were uneventful without contaminations, 
indicating the safety and feasibility of our system 
for preparing ZAK cells. Our system can permit 
ZAK cell generation in a patient with almost no 
limitation. That more transfers of ZAK cells may 
be more effective for cancer treatments suggests 
the requirement of and need for a large-scale cell 
processing center in our hospital.  In addition to this 
proposal, it is worth noting the difficulties when 
considering that the law of good manufacturing 
practice (GMP)/good tissue practice (GTP) for cell-
engineering therapy has not yet been established in 
Japan, although it is highly accelerated, recently 13）. 
This law is urgently required and necessary for 
future progress in this field as well as in regenerative 
medicine.
   The survival analysis implied marginal benefits in 
a few cancer types and a promising benefit in biliary 
tract cancer patients, whose OS was 11.9 months. 
Sasaki et al. conducted a randomized phase II 
study of gemcitabine and S-1 combination therapy 
versus gemcitabine monotherapy for advanced 
biliary tract cancer, and demonstrated that overall 
survivals of these two treatments were 8.9 vs. 9.2 
months, respectively 14）. That the most patients 
in our observational study had been treated with 
chemotherapy before our ZAK cell treatment makes 
our 11.9 months of OS in biliary tract cancer patients 
highly significant. Shimizu et al. demonstrated 
that the 5-year progression-free survival (PFS) and 
overall survival (OS) were prolonged in the group 
receiving AIT plus vaccination with autologous tumor 
lysate-pulsed DCs compared with those receiving 
surgery alone 15）, indicating a survival benefit of AIT 
in the biliary cancers. Moreover, in our pancreatic 
cancer cohort, patients who received ZAK cells 
more than 5 times showed MST of 12.1 months 
(data not shown). Kawaoka et al. reported that AIT 
using activated autologous lymphocytes stimulated 
by the MUC1-expressing human pancreatic cancer 
cell line prolonged the survival with reducing 
liver metastases after surgery 16）, also indicating a 
possible survival benefit of AIT in pancreatic cancer. 
Now, we are conducting a new AIT trial of a phase 
II setting using ZAK cells combined with oral S-1 
administration as the first line treatment for patients 
with unresectable or metastatic pancreatic cancer. 
Here, we have to search adequate biomarkers that 
predict patients suitable for ZAK cell transfers.
   In contrast to the survival benefit, objective tumor 
response was evident in a few patients (13.2 %) 
treated in combination with chemotherapy. It was 
reported that objective tumor response was shown in 
only one of more than 300 prostatic cancer patients 
enrolled in a vaccine trial of the sipuleucel-T 17）, 
suggesting that immunotherapy may prolong the 
survival without tumor shrinkage. Researchers in 
this field should pay more attention on this survival 
benefit of immunotherapy.
   Most importantly, AIT with ZAK cell transfer 
showed the improvement of QOL in patients with 
incurable cancer. Wu et al. demonstrated that QOL 
assessments were significantly improved in lung 
cancer patients treated with chemotherapy plus 
cytokine-induced killer lymphocytes compared 
to those treated with chemotherapy alone 18）, 
suggesting the QOL benefit of AIT. Although we 
have informed correctly the ‘not-yet-proven’ 
efficacy of our AIT for survival and tumor response 
benefit in this prospective study, 228 patients were 
rapidly enrolled during 3 years and 3 months, which 
is possibly indicative of the number of patients 
nationwide willing to seek alternative and additional 
treatments after experiencing the failure of standard 
therapies in Japan. Many patients continue to search 
for promising and successful cancer treatments, even 
those accepting their own fate of being terminally 
ill. For these patients, we have a responsibility and 
duty to proactively prepare adequate supportive 
care systems, like the ZAK cell transfer. It is highly 
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warranted that AIT using autologous activated 
lymphocyte, including ZAK cells, should be 
established urgently based on the views, not only for 
tumor eradication and prolonging patient survival, 
but importantly also for improving peoples quality 
of life.
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